Patents by Inventor Larry L. Green
Larry L. Green has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140154243Abstract: Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.Type: ApplicationFiled: November 21, 2013Publication date: June 5, 2014Applicants: AMGEN FREMONT INC., AMGEN INC.Inventors: Teresa L BURGESS, Angela COXON, Larry L GREEN, Ke ZHANG
-
Patent number: 8710191Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.Type: GrantFiled: August 17, 2009Date of Patent: April 29, 2014Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Publication number: 20140086914Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: October 17, 2013Publication date: March 27, 2014Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: NEIL R. MICHAUD, SHAMA KAJIJI, GARY BORZILLO, VAHE BEDIAN, KEVIN G. COLEMAN, LARRY L. GREEN, XIAO-CHI JIA
-
Publication number: 20130344514Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.Type: ApplicationFiled: August 23, 2013Publication date: December 26, 2013Applicant: AMGEN FREMONT INC.Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
-
Patent number: 8609090Abstract: Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.Type: GrantFiled: July 16, 2004Date of Patent: December 17, 2013Assignees: Amgen Inc., Amgen Fremont Inc.Inventors: Teresa L. Burgess, Angela Coxon, Larry L. Green, Ke Zhang
-
Patent number: 8597615Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.Type: GrantFiled: May 8, 2012Date of Patent: December 3, 2013Assignee: Amgen Fremont Inc.Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
-
Patent number: 8562985Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: GrantFiled: April 24, 2012Date of Patent: October 22, 2013Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120321614Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: April 24, 2012Publication date: December 20, 2012Applicants: Pfizer, Inc., Amgen Fremont Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120219976Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.Type: ApplicationFiled: May 8, 2012Publication date: August 30, 2012Applicant: AMGEN FREMONT INC.Inventors: SIRID-AIMÉE KELLERMANN, LARRY L. GREEN, WOUTER KORVER
-
Patent number: 8198508Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.Type: GrantFiled: October 12, 2009Date of Patent: June 12, 2012Assignee: Amgen Fremont, Inc.Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
-
Patent number: 8163280Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: GrantFiled: January 26, 2009Date of Patent: April 24, 2012Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120058122Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: ApplicationFiled: April 15, 2010Publication date: March 8, 2012Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges, Larry L. Green
-
Publication number: 20120052073Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: ApplicationFiled: June 27, 2011Publication date: March 1, 2012Applicant: Medlmmune LimitedInventors: Larry L. Green, Qing Zhou, Bruce A. Keyt, Xiao-Dong Yang, Stephen Charles Emery, David Charles Blakey
-
Publication number: 20110274696Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided.Type: ApplicationFiled: August 17, 2009Publication date: November 10, 2011Applicants: AMGEN FREMONT INC., PFIZER INC.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Patent number: 7973140Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: December 19, 2005Date of Patent: July 5, 2011Assignee: MedImmune LimitedInventors: Larry L. Green, Qing Zhou, Bruce A. Keyt, Xiao-Dong Yang, Stephen Charles Emery, David Charles Blakey
-
Patent number: 7932372Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies.Type: GrantFiled: July 10, 2006Date of Patent: April 26, 2011Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Nicholas Pullen, Elizabeth Molloy, Sirid-Aimée Kellermann, Larry L. Green, Mary Haak-Frendscho
-
Publication number: 20110091455Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.Type: ApplicationFiled: August 26, 2010Publication date: April 21, 2011Applicants: AMGEN FREMONT INC., AGOURON PHARMACEUTICALS, INC.Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachwieja
-
Patent number: 7807159Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.Type: GrantFiled: April 24, 2006Date of Patent: October 5, 2010Assignees: Amgen Fremont Inc., Agouron Pharmaceuticals, Inc.Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachweija
-
Patent number: 7705130Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: GrantFiled: January 3, 2007Date of Patent: April 27, 2010Assignees: U3 Pharma GmbH, Amgen, Inc.Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Eric Borges, Larry L. Green
-
Publication number: 20100040629Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: January 26, 2009Publication date: February 18, 2010Applicants: Abgenix, Inc., Pfizer, Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia